Skip to content
value.today

3-V Biosciences, Inc.

🇺🇸 Palo Alto, California, USABiotechnologyFounded 2006
Total raised
$167 M
7 rounds on record
Latest round
$69 M
Dec 2020
First round on record
Jul 2009
Today
Went public
See the company page

3-V Biosciences, Inc. is listed today as Sagimet Biosciences Inc.: market value, financials and filings are on its company page.

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of 3-V Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2020$69 MNo. 7$50 to $250 million

3-V Biosciences, Inc.: Raise no. 7, Dec 2020

Investors in this round

13 investors had bought by the notice of Jan 5, 2021: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$69 M of $80 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis Hom · Executive Officer
  • George Kemble · Executive Officer, Director
  • Beth Seidenberg · Director
  • Gordon Ringold · Director
  • James Young · Director
  • Jason Fuller · Director
  • Jinzi Jason Wu · Director
  • Merdad Parsey · Director
  • Richard Rodgers · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Dennis Hom, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 5, 2021. Read the notice at the SEC.

equitySEC
Feb 2019$35 MNo. 6$10 to $50 million

3-V Biosciences, Inc.: Raise no. 6, Feb 2019

Investors in this round

19 investors had bought by the notice of Feb 25, 2019: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$35 M of $42 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis Jason Hom · Executive Officer
  • George Kemble · Executive Officer, Director
  • Beth Seidenberg · Director
  • David Mott · Director
  • Gordon Ringold · Director
  • James Young · Director
  • Jason Fuller · Director
  • Jinzi Jason Wu · Director
  • Merdad Parsey · Director
  • Richard Rodgers · Director
  • Xufang Jason Duan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total amount sold includes $20,224,082.12 in principal and interest from convertible promissory notes that was converted to Series E Preferred Stock.”
  • On the use of proceeds: “General corporate purposes.”

Signed by George Kemble, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 25, 2019. Read the notice at the SEC.

equitySEC
Jun 2016$5 MNo. 5$2 to $10 million

3-V Biosciences, Inc.: Raise no. 5, Jun 2016

Investors in this round

7 investors had bought by the notice of Jul 5, 2016: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $12 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • George Kemble · Executive Officer, Director
  • Beth Seidenberg · Director
  • David Mott · Director
  • Gordon Ringold · Director
  • James Young · Director
  • Jason Fuller · Director
  • Merdad Parsey · Director
  • Richard Rodgers · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by George Kemble, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 5, 2016. Read the notice at the SEC.

equity, debtSEC
Oct 2014$14 MNo. 4$10 to $50 million

3-V Biosciences, Inc.: Raise no. 4, Oct 2014

Investors in this round

12 investors had bought by the notice of Mar 17, 2015: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $35 M offered; $21 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Merdad Parsey · Executive Officer, Director
  • Rekha Hemrajani · Executive Officer
  • Beth Seidenberg · Director
  • David Mott · Director
  • Gordon Ringold · Director
  • James Young · Director
  • Richard Rodgers · Director
  • Robert Garland · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Merdad Parsey, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 17, 2015. Read the notice at the SEC.

equitySEC
Jun 2013$8 MNo. 3$2 to $10 million

3-V Biosciences, Inc.: Raise no. 3, Jun 2013

Investors in this round

2 investors had bought by the notice of Jun 27, 2013: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $20 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Merdad Parsey · Executive Officer, Director
  • Ari Helenius · Director
  • Beth Seidenberg · Director
  • David Mott · Director
  • Gordon Ringold · Director
  • James Young · Director
  • Robert Garland · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total offering amount includes the purchase price of the Series C Preferred Stock, the purchase price of the Common Stock Warrants and the potential proceeds from the exercise of the Common Stock Warrants.”
  • On the use of proceeds: “The proceeds will be used for working capital.”

Signed by Merdad Parsey, MD, Ph.D, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 27, 2013. Read the notice at the SEC.

equity, optionsSEC
Nov 2011$20 MNo. 2$10 to $50 million

3-V Biosciences, Inc.: Raise no. 2, Nov 2011

Investors in this round

3 investors had bought by the notice of Dec 20, 2012: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $25 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Merdad Parsey · Executive Officer, Director
  • Ari Helenius · Director
  • Beth Seidenberg · Director
  • David Mott · Director
  • Gordon Ringold · Director
  • James Young · Director
  • Robert Garland · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The amount sold includes the purchase price of the warrants and the stock.”
  • On the use of proceeds: “The proceeds will be used for working capital.”

Signed by Merdad Parsey, MD, Ph.D, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 20, 2012. Read the notice at the SEC.

equity, optionsSEC
Jul 2009$15 MNo. 1$10 to $50 million

3-V Biosciences, Inc.: Raise no. 1, Jul 2009

Investors in this round

4 investors had bought by the notice of Jul 22, 2009: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $30 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Curnutte · Executive Officer, Director
  • Rick Klausner · Executive Officer, Director
  • Ari Helenius · Director
  • Beth Seidenberg · Director
  • David Mott · Director
  • Gordon Ringold · Director
  • Robert Garland · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The proceeds shall be used for working capital.”

Signed by Glen Sato, Secretary. Source: SEC Form D, newest notice filed Jul 22, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • 3-V Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2021).

    SEC Form D · Jan 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2021

That is all the official record says: 3-V Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of 3-V Biosciences, Inc. are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in 3-V Biosciences, Inc.
InvestorKindAmountRoundRoleSource
Beth C. SeidenbergPersonnot statednot statedHeld Series E preferred stock, director (Form 3, 2023)SEC Form 3
Kpcb Pandemic & Bio Defense Fund LLCFund or asset managernot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2023)SEC Form 3
KPCB PBD Associates, LLCOthernot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Merdad ParseyPersonnot statednot statedHeld Series E preferred stock, director (Form 3, 2023)SEC Form 3
NEA 13 GP, LtdCompanynot statednot statedHeld Series B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2023)SEC Form 3
NEA Partners 13, Limited PartnershipFund or asset managernot statednot statedHeld Series B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2023)SEC Form 3
New Enterprise Associates 13 LPFund or asset managernot statednot statedHeld Series B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Timothy P. WalbertPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2024)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 19 investors.

Largest shareholders today

Institutions holding Sagimet Biosciences Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by 3-V Biosciences, Inc.
NameRoleNamed in
Dennis HomExecutive officerJan 2021
George KembleExecutive officerJan 2021
Dennis Jason HomExecutive officerFeb 2019
Merdad ParseyExecutive officerMar 2015
Rekha HemrajaniExecutive officerMar 2015
John CurnutteExecutive officerJul 2009
Rick KlausnerExecutive officerJul 2009
Beth SeidenbergDirectorJan 2021
George KembleDirectorJan 2021
Gordon RingoldDirectorJan 2021
James YoungDirectorJan 2021
Jason FullerDirectorJan 2021
Jinzi Jason WuDirectorJan 2021
Merdad ParseyDirectorJan 2021
Richard RodgersDirectorJan 2021
David MottDirectorFeb 2019
Xufang Jason DuanDirectorFeb 2019
Robert GarlandDirectorMar 2015
Ari HeleniusDirectorJun 2013
John CurnutteDirectorJul 2009
Rick KlausnerDirectorJul 2009

Went public since 2023. Its SEC number is that of a company listed on a stock exchange.